Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)

Trial Profile

Management of Parkinson's Disease Psychosis in Actual Practice (The INSYTE Study)

Status: Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Nov 2018

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Pimavanserin (Primary) ; Aripiprazole; Clozapine; Olanzapine; Quetiapine
  • Indications Parkinson's disease
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors Acadia Pharmaceuticals
  • Most Recent Events

    • 29 Nov 2018 New trial record
    • 14 Nov 2018 Interim results (n=90) presented at the 21st Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top